In this webinar, Martin Stahl, PhD, describes how patient-derived organoids can be used to study intestinal barrier function as well as the toxicity of potential therapeutic compounds.

Highlights

  • An overview of intestinal organoids and their advantages.
  • Studying intestinal barrier toxicity and permeability.
  • Organoid tools and services available from STEMCELL.

Webinar Summary

Since their first publication in 2009, intestinal organoids have proven to be an invaluable resource for preclinical research. Organoids are in vitro organ-specific cells that develop from stem cells and replicate the cell structure and complexity of a real organ. Since organoids can be grown from both pluripotent and adult stem cells, they can exemplify diverse patient genotypes and phenotypes that are not often seen in traditional cell lines. In this webinar, Dr. Stahl describes key benefits of organoids over traditional cell lines in drug discovery, as well as their applications in assessing drug toxicity and permeability of the epithelium. 

“What we’re really trying to do [with intestinal organoids] is replicate that stem cell niche… we’re trying to replicate the factors the stem cells need … to divide and differentiate.”

One of the main benefits of using organoids in drug discovery in lieu of traditional cell lines is the ability to monitor interactions between the various cell types that make up a tissue. Intestinal organoid differentiation begins with LGR5-positive stem cells located in the epithelium, which are either harvested from patient samples, or induced from human embryonic or induced pluripotent stem cells. By supplying the correct growth factors,  these cells will differentiate, proliferate, and form tight intercellular junctions much like they would in vivo. As these organoids are self-replenishing, they far outlast traditional cell lines in culture and can provide a more realistic model of intestinal physiology.

Intestinal organoids are an important tool for drug development and discovery as they represent the point of entry for most pharmaceutical compounds. Before a drug enters the bloodstream, it must first be absorbed into the intestinal lumen. However, this process is inefficient and poses a risk for drug degradation. Intestinal barrier permeability and toxicity are major factors in drug pipeline attrition and are crucial components to consider when assessing any pharmaceutical candidate. A healthy intestinal epithelium maintains a restrictive barrier that is maintained by a series of tight junctions in between epithelial cells as well as a layer of mucus. Damage to these intercellular junctions would drastically impair the regulation of what enters or exits the intestines.

“If you start losing that [intestinal] barrier, … [you’re] going to start getting a strong immune response … [and] you can start getting sepsis.”

Intestinal organoids present a unique opportunity to study these toxicological effects as they allow for high throughput assays that are not achievable in animal models, and are more physiologically accurate than cell models. Dr. Stahl compares how intestinal organoids grown with IntestiCult Organoid Growth Medium and Caco-2, a common cell line used to study the intestinal barrier,  respond to a variety of pharmaceuticals, including chemotherapy drugs, an epidermal growth factor receptor (EGFR) inhibitor, and an anti-gout agent. For example, 5-fluorouracil was shown to have greater effects on the intestinal organoids than Caco-2 since it reduces cell count through a loss of proliferation rather than cell death.

Although intestinal organoids are beneficial for studying the intestinal barrier, they must first be plated in a monolayer culture when assessing barrier strength. This allows the 3D structure and mucous layer of the epithelium to be established. Dr. Stahl has employed two assay techniques to determine the quality and strength of the intestinal barrier: FITC-dextran permeability and transepithelial electrical resistance (TEER). In addition to determining membrane properties, these assays are advantageous in analyzing intestinal barrier degradation in response to drug administration. For example when Dr. Stahl administered a high concentration of colchicine, an anti-gout agent that targets proliferating cells, he noted a very different response from Caco-2 and the organoid. The cell line showed no significant response whereas the intestinal organoid rapidly degraded, highlighting the physiological differences between these two models.

Intestinal organoids can provide a unique advantage to researchers at any stage of research. In addition to accelerating preclinical testing, intestinal organoids also provide the opportunity to capture drug side effects that are not typically observed with traditional cell lines. Therefore, organoids can help researchers capture a more realistic image of what happens in the intestine and allow for patient-specific treatment plans.

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video viewer.

Resources

Q&A

  • In regards to drug testing, is it more physiologically relevant to treat organoids grown in growth media or differentiation media?
  • Would increasing differentiation with various media reduce any of the potential differences that you might see based on phenotype?
  • Could intestinal organoids be used to study drug absorption or other pharmacokinetics?
  • How do you account for the inherent variability of organoid systems and how might that affect the readout of an assay?
  • Can organoids be co-cultured with immune cells or other cell types?
  • Can we maintain epigenetic patterns in organoids obtained from patient samples?
  • Could 3D human intestinal organoids also form structures with villus-like and crypt-like domains after differentiation?
  • How do you measure cell viability in 3D organoids?
  • How do you account for differences in cell numbers between organoids from different patients when comparing dose response curves?
  • Do you observe similar growth and differentiation levels in 2D monolayers and 3D organoids?
  • How would you exclude the effect of growth factors found in culture media while doing a drug treatment?
  • What image analysis challenges are encountered when working with organoids?

Presenters

Senior Scientist
Research and Development
STEMCELL Technologies

After completing his PhD and postdoctoral research, Martin received a fellowship to work jointly between the Vallance lab at UBC and STEMCELL Technologies, developing new ways of employing intestinal organoids in academic research. Now a Senior Scientist at STEMCELL, Martin's work focuses on developing new media and applications for intestinal organoid products.

Production Partner

STEMCELL Technologies Inc.

STEMCELL Technologies provides specialized cell culture media, cell isolation products, and reagents for your cell therapy and drug discovery research. Our ethically sourced human primary cell portfolio includes products from peripheral blood, cord blood, and bone marrow.

Additional Content From STEMCELL Technologies Inc.

Additional Content From Scientist.com

COMPLi HBS Legislation Series: France

COMPLi HBS Legislation Series: France

This webinar explores France's governance of human biological samples for research, focusing on acquisition, storage, import/export, and unique requirements in comparison to global standards.

Related Content